Table 2.
Effects for in utero ETS exposure (no/yes), the SNPs, and the interaction of GSTO SNPs (recessive model) with in utero ETS exposure on FEV1
| |
FEV1 (ml) b (95% CI) |
|
||
|---|---|---|---|---|
| Gene | Variable | All | Never smokers | Ever smokers |
| |
N, in analysis |
6003 |
2576 |
3427 |
|
GSTO1 |
In utero ETS |
−33 (−69 ; 4) |
−25 (−81 ; 32) |
−43 (91 ; 5) |
| |
rs4925 |
−33 (−77 ; 10) |
−1 (65 ; 63) |
−58 (−117 ; 1) |
| |
ETS*rs4925 |
$177 (50 ; 305)** |
196 (15 ; 376)* |
161 (−18 ; 340) |
|
GSTO1 |
In utero ETS |
−40 (−77 ; -2)* |
−32 (−89 ; 26) |
−51 (−100 ; -2)* |
| |
rs1147611 |
−22 (−58 ; 14) |
6 (−46 ; 58) |
−46 (−96 ; 3) |
| |
ETS*rs1147611 |
$177 (72 ; 283)*** |
$206 (47 ; 365)* |
166 (25 ; 307)* |
|
GSTO2 |
In utero ETS |
−41 (−78 ; -3)* |
−28 (−85 ; 30) |
−55 (−104 ; -6)* |
| |
rs156697 |
−28 (−64 ; 9) |
9 (−44 ; 62) |
−59 (−110 ; -8)* |
| |
ETS*rs156697 |
$198 (90 ; 307)*** |
181 (20 ; 342)* |
$219 (72 ; 366)** |
|
GSTO2 |
In utero ETS |
−33 (−70 ; 3) |
−24 (−81 ; 32) |
−45 (−93 ; 4) |
| |
rs156699 |
−30 (−70 ; 10) |
−9 (−66 ; 49) |
−48 (−104 ; 7) |
| ETS*rs156699 | $160 (41 ; 278)** | 193 (12 ; 374)* | 143 (−15 ; 300) | |
The linear regression model for the whole group was adjusted for sex, age, height, weight, current, ex-smoking and packyears smoked. Consequently we stratified by smoking status (never/ever) and adjusted for the other possible confounders.
*p-value<0.05 **p-value<0.01 *** p-value<0.001.
$significant after FDR correction for multiple testing.